Shiota H, Inoue S, Yamane S
Br J Ophthalmol. 1979 Jun;63(6):425-8. doi: 10.1136/bjo.63.6.425.
The effect of a new antiherpetic compound of very low toxicity called acycloguanosine (Wellcome 248U) on herpetic ulcers in rabbit cornea was studied by the Corneal Epithelial Lesion Therapeutic Assay (CELTA). The therapeutic effect of 3% acycloguanosine ointment on dendritic ulcers was equal to that of 0.5% 5-iodo-2'-deoxyuridine (IDU) ointment. No toxic symptoms could be detected by slit-lamp on 4 days' treatment with this concentration of acycloguanosine. Because of its selective action on virus only, its extremely low toxicity in animals, and its availability for systemic administration, acycloguanosine seems to be an ideal antiviral compound for use in the treatment not only of herpetic keratitis but also of other herpetic diseases in man.
采用角膜上皮病变治疗试验（CELTA）研究了一种名为阿昔洛韦（韦尔科姆248U）的低毒新型抗疱疹化合物对兔角膜疱疹性溃疡的作用。3%阿昔洛韦软膏对树枝状溃疡的治疗效果与0.5% 5-碘-2'-脱氧尿苷（IDU）软膏相当。用该浓度的阿昔洛韦治疗4天，裂隙灯检查未发现毒性症状。由于其仅对病毒有选择性作用、在动物体内毒性极低且可用于全身给药，阿昔洛韦似乎是一种理想的抗病毒化合物，不仅可用于治疗疱疹性角膜炎，还可用于治疗人类的其他疱疹性疾病。
